Functional and bioenergetic consequences of AT1 antagonist olmesartan medoxomil in hearts with postinfarction LV remodeling

Journal of Cardiovascular Pharmacology

Volumn 47, Issue 5, 2006, Pages 686-694

  Ochiai, Koichi ^a,b   Hu, Qingsong ^a   Lee, Joseph ^a   Mansoor, Abdul ^a   Liu, Jingbo ^a   Wang, Xiaohong ^a   Gong, Guangrong ^a   Murakami, Yo ^a,b   Ishibashi, Yukada ^a   Shimada, Toshio ^a,b   Zhang, Jianyi ^a,c  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b SHIMANE UNIVERSITY   (Japan)

^c University of Minnesota   (United States)

Author keywords

Heart failure; High energy phosphates; Hypertrophy; Myocardial energetics; Myocardial infarction; Nuclear magnetic resonance spectroscopy

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CREATINE PHOSPHATE; OLMESARTAN; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE;

ACUTE HEART INFARCTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA PRESSURE; ARTICLE; ASCITES; BIOENERGY; BODY WEIGHT; CELLULAR DISTRIBUTION; COMPARATIVE STUDY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORONARY ARTERY LIGATION; DISEASE SEVERITY; DOSE CALCULATION; DRUG EFFECT; ENDOCARDIUM; ENZYME RELEASE; ENZYME SUBUNIT; EVIDENCE BASED MEDICINE; HEART MUSCLE BLOOD FLOW; HEART MUSCLE OXYGEN CONSUMPTION; HEART MUSCLE PERFUSION; HEART VENTRICLE FUNCTION; HEART VENTRICLE REMODELING; HEMODYNAMICS; MITOCHONDRION; NONHUMAN; PRIORITY JOURNAL; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SWINE; TREATMENT OUTCOME;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; CORONARY VESSELS; ENERGY METABOLISM; HEART; HEART FAILURE, CONGESTIVE; IMIDAZOLES; MAGNETIC RESONANCE SPECTROSCOPY; MITOCHONDRIA; MYOCARDIAL INFARCTION; OXYGEN CONSUMPTION; PHOSPHATES; PROTON-TRANSLOCATING ATPASES; RENIN-ANGIOTENSIN SYSTEM; SWINE; TETRAZOLES; VENTRICULAR REMODELING;

EID: 33748195463     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fjc.0000211760.29141.c1     Document Type: Article

References (33)

1. Liu J, Wang C, Murakami Y, et al. Mitochondrial ATPase and high-energy phosphates in failing hearts. Am J Physiol Heart Circ Physiol. 2001;281:H1319-H1326.
2. Murakami Y, Zhang Y, Cho YK, et al. Myocardial oxygenation during high work states in hearts with postinfarction remodeling. Circulation. 1999;99:942-948.
3. Zhang J, Wilke N, Wang Y, et al. Functional and bioenergetic consequences of postinfarction left ventricular remodeling in a new porcine model. MRI and 31 P-MRS study. Circulation. 1996;94:1089-1100.
4. Neubauer S, Horn M, Cramer M, et al. Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation. 1997;96:2190-2196.
5. Ye Y, Gong G, Ochiai K, et al. High-energy phosphate metabolism and creatine kinase in failing hearts: a new porcine model. Circulation. 2001;103:1570-1576.
6. Zhang J, Merkle H, Hendrich K, et al. Bioenergetic abnormalities associated with severe left ventricular hypertrophy. J Clin Invest. 1993;92:993-1003.
7. Zhang J, Toher C, Erhard M, et al. Relationships between myocardial bioenergetic and left ventricular function in hearts with volume-overload hypertrophy. Circulation. 1997;96:334-343.
8. Buchthal SD, den Hollander JA, Merz CN, et al. Abnormal myocardial phosphorus-31 nuclear magnetic resonance spectroscopy in women with chest pain but normal coronary angiograms. N Engl J Med. 2000;342:829-835.
9. Conway MA, Bottomley PA, Ouwerkerk R, et al. Mitral regurgitation: impaired systolic function, eccentric hypertrophy, and increased severity are linked to lower phosphocreatine/ATP ratios in humans. Circulation. 1998;97:1716-1723.
10. Capasso JM, Li P, Meggs LG, et al. Efficacy of angiotensin-converting enzyme inhibition and AT1 receptor blockade on cardiac pump performance after myocardial infarction in rats. J Cardiovasc Pharmacol. 1994;23:584-593.
11. Schieffer B, Wirger A, Meybrunn M, et al. Comparative effects of chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on cardiac remodeling after myocardial infarction in the rat. Circulation. 1994;89:2273-2282.
12. Institute of Laboratory Animal Resources (US). Guide for the Care and Use of Laboratory Animals. Washington, DC: National Academy Press; 1996.
13. Puchler K, Nussberger J, Laeis P, et al. Blood pressure and endocrine effects of single doses of CS-866, a novel angiotensin II antagonist, in salt-restricted hypertensive patients. J Hypertens. 1997;15:1809-1812.
14. Schwocho LR, Masonson HN. Pharmacokinetics of CS-866, a new angiotensin II receptor blocker, in healthy subjects. J Clin Pharmacol. 2001;41:515-527.
15. Liu H, Zhang J. An efficient MR phosphorous spectroscopic localization technique for studying ischemic heart. J Magn Reson Imaging. 1999;10:892-898.
16. Meggs LG, Coupet J, Huang H, et al. Regulation of angiotensin II receptors on ventricular myocytes after myocardial infarction in rats. Circ Res. 1993;72:1149-1162.
17. Tan J, Wang H, Leenen FH. Increases in brain and cardiac AT1 receptor and ACE densities after myocardial infarct in rats. Am J Physiol Heart Circ Physiol. 2004;286:H1665-H1671.
18. Lijnen PJ, Petrov VV. Role of intracardiac renin-angiotensin-aldosterone system in extracellular matrix remodeling. Methods Find Exp Clin Pharmacol. 2003;25:541-564.
19. Simonis G, Dahlem MH, Hohlfeld T, et al. A novel activation process of protein kinase C in the remote, non-ischemic area of an infarcted heart is mediated by angiotensin-AT1 receptors. J Mol Cell Cardiol. 2003;35:1349-1358.
20. Toko H, Zou Y, Minamino T, et al. Angiotensin II type 1a receptor is involved in cell infiltration, cytokine production, and neovascularization in infarcted myocardium. Arterioscler Thromb Vasc Biol. 2004;24:664-670.
21. Thai H, Wollmuth J, Goldman S, et al. Angiotensin subtype 1 receptor (AT1) blockade improves vasorelaxation in heart failure by up-regulation of endothelial nitric-oxide synthase via activation of the AT2 receptor. J Pharmacol Exp Ther. 2003;307:1171-1178.
22. Hugel S, Horn M, de Groot M, et al. Effects of ACE inhibition and beta-receptor blockade on energy metabolism in rats postmyocardial infarction. Am J Physiol. 1999;277:H2167-H2175.
23. Lawson JW, Veech RL. Effects of pH and free Mg2+ on the Keq of the creatine kinase reaction and other phosphate hydrolyses and phosphate transfer reactions. J Biol Chem. 1979;254:6528-6537.
24. Tian R, Ingwall JS. Energetic basis for reduced contractile reserve in isolated rat hearts. Am J Physiol. 1996;270:H1207-H1216.
25. Sanbe A, Tanonaka K, Kobayasi R, et al. Effects of long-term therapy with ACE inhibitors, captopril, enalapril and trandolapril, on myocardial energy metabolism in rats with heart failure following myocardial infarction. J Mol Cell Cardiol. 1995;27:2209-2222.
26. Horn M, Neubauer S, Frantz S, et al. Preservation of left ventricular mechanical function and energy metabolism in rats after myocardial infarction by the angiotensin-converting enzyme inhibitor quinapril. J Cardiovasc Pharmacol. 1996;27:201-210.
27. Werrmann JG, Cohen SM. Comparison of effects of angiotensin-converting enzyme inhibition with those of angiotensin II receptor antagonism on functional and metabolic recovery in postischemic working rat heart as studied by [31P] nuclear magnetic resonance. J Cardiovasc Pharmacol. 1994;24:573-586.
28. Kawabata H, Ryomoto T, Ishikawa K. Cardioprotection with angiotensin converting enzyme inhibitor and angiotensin II type 1 receptor antagonist is not abolished by nitric oxide synthase inhibitor in ischemia-reperfused rabbit hearts. Hypertens Res. 2001;24:403-409.
29. Kawabata H, Ryomoto T, Ishikawa K. Effect of angiotensin converting enzyme inhibitor and angiotensin II type 1 receptor antagonist on metabolism and contraction in ischemia-reperfused rabbit heart. Jpn Circ J. 2000;64:276-282.
30. Kawabata H, Ryomoto T, Ishikawa K. Role of cardiac ATP-sensitive K+ channels induced by angiotensin II type 1 receptor antagonist on metabolism, contraction and relaxation in ischemia-reperfused rabbit heart. Jpn Circ J. 2001;65:451-456.
31. Domenech RJ, Hoffman JI, Noble MI, et al. Total and regional coronary blood flow measured by radioactive microspheres in conscious and anesthetized dogs. Circ Res. 1969;25:581-596.
32. Liao R, Jain M, Cui L, et al. Cardiac-specific overexpression of GLUT1 prevents the development of heart failure attributable to pressure overload in mice. Circulation. 2002;106:2125-2131.
33. Spindler M, Engelhardt S, Niebler R, et al. Alterations in the myocardial creatine kinase system precede the development of contractile dysfunction in beta(1)-adrenergic receptor transgenic mice. J Mol Cell Cardiol. 2003;35:389-397.